Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Prediction of Adverse Outcomes in Children with Sickle Cell Disease

Abstract

BACKGROUND: The ability to identify infants with sickle cell anemia who are likely to have severe complications later in life would permit accurate prognostication and tailoring of therapy to match disease-related risks and facilitate planning of clinical trials. We attempted to define the features of such babies by following the clinical course of 392 children with sickle cell disease from infancy to about the age of 10 years. METHODS: We analyzed the records of 392 infants who received the diagnosis of homozygous sickle cell anemia or sickle cell-Beta(0)-thalassemia before the age of six months and for whom comprehensive clinical and laboratory data were recorded prospectively; data were available for a mean (+/-SD) of 10.0+/-4.8 years. Results obtained before the age of two years were evaluated to determine whether they predicted the outcome later in life. RESULTS: Of the 392 infants in the cohort, 70 (18 percent) subsequently had an adverse outcome, defined as death (18 patients [26 percent]), stroke (25 [36 percent]) frequent pain (17 [24 percent]), or recurrent acute chest syndrome (10 [14 percent]). Using multivariate analysis, we found three statistically significant predictors of an adverse outcome: an episode of dactylitis before the age of one year (relative risk of an adverse outcome, 2.55; 95 percent confidence interval, 1.39 to 4.67), a hemoglobin level of less than 7 g per deciliter (relative risk, 2.47; 95 percent confidence interval, 1.14 to 5.33), and leukocytosis in the absence of infection (relative risk, 1.80; 95 percent confidence interval, 1.05 to 3.09). CONCLUSIONS: Three easily identifiable manifestations of sickle cell disease that may appear in the first two years of life (dactylitis, severe anemia, and leukocytosis) can help to predict the possibility of severe sickle cell disease later in life.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm200001133420203

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Research works printed but not linked: 6

  1. Ohene-Frempong K, 1998, Blood, 91, 288
  2. Bray GL, 1994, Am J Pediatr Hematol Oncol, 16, 50
  3. Gaston MH, 1982, Am J Pediatr Hematol Oncol, 4, 197
  4. Moser FG, 1996, AJNR Am J Neuroradiol, 17, 965
  5. Koshy M, 1990, J Assoc Acad Minor Phys, 1, 71
  6. Powars DR, 1991, Semin Hematol, 28, 202

Cited by

See all 508

Metadata

Authors
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R.
Affiliations
  • State University of New York (US)
  • New England Research Institutes (US)
  • University of Miami (US)
  • St. Jude Children's Research Hospital (US)
  • St. Luke's-Roosevelt Hospital Center (US)
  • Harlem Hospital Center (US)
  • Duke Medical Center (US)
Venue
New England Journal of Medicine
Published
2000-01-13
Volume
342
Issue
2
Pages
83-89
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1982989569
Cited by
508
References
41
Citations by year
2026: 7 · 2025: 7 · 2024: 12 · 2023: 22 · 2022: 15 · 2021: 25 · 2020: 10 · 2019: 14 · 2018: 18 · 2017: 15 · 2016: 21 · 2015: 17 · 2014: 21 · 2013: 14 · 2012: 24
FWCI
13.30
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01hb047110-008)
  • National Heart, Lung, and Blood Institute (N01-HB-47110)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
Keywords
sickle cell disease, sickle beta-thalassemia, adverse outcome prediction, prognosis, dactylitis, severe anemia, leukocytosis, stroke, acute chest syndrome, child mortality, infants
MeSH terms
Anemia, Anemia, Sickle Cell, Extremities, Humans, Infant, Inflammation, Leukocytosis, Pain, Prognosis, Retrospective Studies, ROC Curve, Severity of Illness Index, Cohort Studies, Multivariate Analysis, Logistic Models, beta-Thalassemia, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prediction of Adverse Outcomes in Children with Sickle Cell Disease. https://app.cochat.ai/papers/10.1056/nejm200001133420203
The paper
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R. (2000). Prediction of Adverse Outcomes in Children with Sickle Cell Disease. New England Journal of Medicine. https://doi.org/10.1056/nejm200001133420203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.